Radiance
Register
Register
Register

Marc Creus

CEO

abbmira therapeutics AG

Basel, Switzerland

Company

Abbmira Therapeutics AG is a Swiss biotech startup fine-tuning the native immune system for improved outcomes in cancer therapy and autoimmune diseases.

My organisation

abbmira therapeutics AG

abbmira therapeutics AG

Company (SME, Spin-off, Start-up)

Basel, Switzerland

At abbmira therapeutics AG, we are dedicated to revolutionizing the field of biomedicine through innovative, proprietary small molecule therapies that fine-tune the immune system to fight disease. Our team specializes in cutting-edge research and preclinical development aimed at addressing unmet medical needs, particularly in the area of immunomodulatory targeted therapies against cancer. We collaborate with industry partners, academics and stakeholders to accelerate drug discovery and bring forth advancements that can improve patient outcomes. Together, we strive to make a meaningful impact in the world of healthcare and drive progress within the pharmaceutical landscape.
Read more

About me

Dr. Marc Creus is a biochemist with broad interests, particularly in science-innovation & tech-transfer both in academia and industry. He has also been involved in several startups and is currently founding CEO of abbmira therapeutics.  At the University of Basel he helped in the establishment of a National Centre of Competence & Research “Antiresist” and currently lectures on the topic Science Communication. Marc is also the founding president of the Advisory Council of the Swiss Young Academy and co-founder of the Science Slam Club Basel. Marc holds a PhD from Cambridge University, is an author of multiple science publications on different topics, a TEDx speaker and also the winner of  the Basel Science Slam in 2013.

Social media

Skills

  • Drug Development
  • immunity
  • innovation
  • discovery
  • small molecules
  • chemistry
  • Biochemistry
  • Macrophages
  • oncology
  • autoimmune diseases
  • Therapeutics
  • preclinical
  • Drug design
  • cancer

Interests

  • Drug Development
  • immunity
  • innovation
  • discovery
  • small molecules
  • chemistry
  • Biochemistry
  • Macrophages
  • R&D
  • oncology
  • autoimmune diseases
  • Therapeutics
  • preclinical
  • Drug design
  • cancer

Marketplace (3)

  • Project cooperation

    Preclinical Immuno-modulatory Drug Development in Oncology

    Abbmira Therapeutics AG is a Basel based biotech company developing novel immune modulators for improved outcomes in cancer therapy.

    • MSCA-PF2025
    • MSCA-DN2025
    • Proposal Idea
    • Proposal under Development
    • POSTDOCTORAL FELLOWSHIP: Looking for an Institution for Secondment
    • DOCTORAL NETWORK: Looking for Partner/s (Beneficiaries or Associated Partners)
    Author

    Marc Creus

    CEO at abbmira therapeutics AG

    Basel, Switzerland

  • Expertise

    Preclinical Immuno-Modulatory Drug Development in Oncology

    Abbmira Therapeutics AG is a Basel based biotech company developing novel immune modulators for improved outcomes in cancer therapy.

    • CHE - Chemistry
    • LIF - Life Sciences
    • DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
    • POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
    Author

    Marc Creus

    CEO at abbmira therapeutics AG

    Basel, Switzerland